TARDBP and leukemia: This type II topoisomerase inhibitor, approved for leukemia and multiple sclerosis, reduces TDP-43 recruitment to SGs and mitigates persistent cytoplasmic TDP-43 aggregates in induced pluripotent stem-cell-derived motor neurons (hiPSC-MNs) [23].